Use of a Heparinoid in Patients with Hemorrhagic Stroke and Thromboembolic Disease

Overview

Journal Ann Neurol

Specialty Neurology

Date 1984 Mar 1

PMID 6721448

Citations 5

Authors

H ten Cate

C P Henny

H R Buller

J W Ten Cate

H N Magnani

Affiliations

Soon will be listed here.

Abstract

A new heparinoid, Org 10172, was given to five patients with hemorrhagic stroke with thromboembolic complications. Treatment did not cause progression of cerebral bleeding, and thrombotic processes were inhibited. No side effects were encountered.

Citing Articles

Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations.

Nurmohamed M, ten Cate H, Ten Cate J Drugs. 1997; 53(5):736-51.

PMID: 9129863 DOI: 10.2165/00003495-199753050-00002.

Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

Mikhailidis D, Fonseca V, Barradas M, Jeremy J, Dandona P Br J Clin Pharmacol. 1987; 24(4):415-24.

PMID: 3689624 PMC: 1386302. DOI: 10.1111/j.1365-2125.1987.tb03193.x.

ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

Bradbrook I, Magnani H, Moelker H, Morrison P, Robinson J, Rogers H Br J Clin Pharmacol. 1987; 23(6):667-75.

PMID: 3606928 PMC: 1386160. DOI: 10.1111/j.1365-2125.1987.tb03100.x.

Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.

Stiekema J, Wijnand H, Van Dinther T, Moelker H, Dawes J, Vinchenzo A Br J Clin Pharmacol. 1989; 27(1):39-48.

PMID: 2468354 PMC: 1379703. DOI: 10.1111/j.1365-2125.1989.tb05333.x.

Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.

de Boer A, Stiekema J, Danhof M, Van Dinther T, Boeijinga J, Cohen A Antimicrob Agents Chemother. 1991; 35(10):2110-5.

PMID: 1759835 PMC: 245335. DOI: 10.1128/AAC.35.10.2110.